| Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma S Yi, Y Yan, M Jin, S Bhattacharya, Y Wang, Y Wu, L Yang, E Gine, G Clot, ... The Journal of clinical investigation 132 (3), 2022 | 50 | 2022 |
| The impact of response kinetics for multiple myeloma in the era of novel agents Y Yan, X Mao, J Liu, H Fan, C Du, Z Li, S Yi, Y Xu, R Lv, W Liu, S Deng, ... Blood Advances 3 (19), 2895-2904, 2019 | 38 | 2019 |
| Raman spectroscopy-based biomarker screening by studying the fingerprint characteristics of chronic lymphocytic leukemia and diffuse large B-cell lymphoma Y Bai, Z Yu, S Yi, Y Yan, Z Huang, L Qiu Journal of Pharmaceutical and Biomedical Analysis 190, 113514, 2020 | 25 | 2020 |
| 1q21 gain but not t (4; 14) indicates inferior outcomes in multiple myeloma treated with bortezomib C Du, X Mao, Y Xu, Y Yan, C Yuan, X Du, J Liu, H Fan, Q Wang, W Sui, ... Leukemia & Lymphoma 61 (5), 1201-1210, 2020 | 24 | 2020 |
| Monitoring the cytogenetic architecture of minimal residual plasma cells indicates therapy-induced clonal selection in multiple myeloma G An, Y Yan, Y Xu, X Mao, J Liu, H Fan, Q Wang, C Du, Z Li, S Yi, R Lv, ... Leukemia 34 (2), 578-588, 2020 | 21 | 2020 |
| High incidence of MYD88 and KMT2D mutations in Chinese with chronic lymphocytic leukemia S Yi, Y Yan, M Jin, W Xiong, Z Yu, Y Yu, R Cui, J Wang, Y Wang, Y Lin, ... Leukemia 35 (8), 2412-2415, 2021 | 19 | 2021 |
| Distinct clinical characteristics draw a new prognostic model for splenic marginal zone lymphoma in HBV high prevalent region S Yi, Y Yan, W Xiong, R Lv, Z Yu, W Liu, E Liu, H Li, H Liu, Z Li, G An, Y Xu, ... Oncotarget 8 (58), 98757, 2017 | 17 | 2017 |
| Clonal phylogeny and evolution of critical cytogenetic aberrations in multiple myeloma at single-cell level by QM-FISH Y Yan, X Qin, J Liu, H Fan, W Yan, L Liu, C Du, Z Yu, Y Xu, M Hao, ... Blood Advances 6 (2), 441-451, 2022 | 13 | 2022 |
| IgH translocation with undefined partners is associated with superior outcome in multiple myeloma patients XH Mao, JL Zhuang, DD Zhao, XQ Li, X Du, M Hao, Y Xu, YT Yan, JH Liu, ... European Journal of Haematology 105 (3), 326-334, 2020 | 11 | 2020 |
| Landscape of immunoglobulin heavy chain gene repertoire and its clinical relevance to LPL/WM J Wang, Y Yan, W Xiong, G Song, Y Wang, J Zhao, Y Jia, C Li, Z Yu, Y Yu, ... Blood Advances 6 (13), 4049-4059, 2022 | 10 | 2022 |
| Subtype distribution, clinical features, and survival in b-cell chronic lymphoproliferative disorders in china: a review of 1592 cases Y Yan, R Lv, W Xiong, Z Li, Y Wang, Y Yu, Z Yu, T Wang, W Sui, W Liu, ... Clinical Lymphoma Myeloma and Leukemia 20 (6), e270-e283, 2020 | 8 | 2020 |
| Single-cell profiles reveal tumor cell heterogeneity and immunosuppressive microenvironment in Waldenström macroglobulinemia H Sun, T Fang, T Wang, Z Yu, L Gong, X Wei, H Wang, Y He, L Liu, Y Yan, ... Journal of Translational Medicine 20 (1), 576, 2022 | 6 | 2022 |
| Del17p does not always significantly influence the survival of B-cell chronic lymphoproliferative disorders S Yi, Z Li, D Zou, W Xiong, H Li, R Cui, C Li, Y Yan, W Liu, R Lv, Z Yu, ... Oncotarget 9 (3), 3353, 2018 | 6 | 2018 |
| Undetectable minimal residual disease is an independent prognostic factor in splenic marginal zone lymphoma R Lyu, T Wang, Y Wang, W Xiong, H Wang, Y Yan, Q Wang, W Liu, G An, ... British Journal of Haematology 194 (5), 862-869, 2021 | 5 | 2021 |
| Prominent immune signatures of T cells are specifically associated with indolent B‐cell lymphoproliferative disorders and predict prognosis S Yi, Y Zhang, W Xiong, W Chen, Z Hou, Y Yang, Y Yan, Y Wei, R Cui, ... Clinical & Translational Immunology 9 (1), e01105, 2020 | 5 | 2020 |
| Purine nucleoside analogs plus rituximab are an effective treatment choice for hairy cell leukemia-variant Y Wang, T Wang, Y Yu, Q Wang, Y Yan, R Li, Q Sun, W Xiong, R Lyu, ... Annals of Hematology 101 (6), 1201-1210, 2022 | 4 | 2022 |
| Zanubrutinib plus ixazomib and dexamethasone for newly diagnosed symptomatic waldenström macroglobulinemia: a prospective, phase II study Y Yu, SH Yi, X Wenjie, T Wang, Y Yan, W Liu, W Sui, G An, Y Xu, H Liu, ... Blood 140 (Supplement 1), 3587-3588, 2022 | 3 | 2022 |
| The relative risk of prognostic factors of age stratified multiple myeloma C Du, Y Wang, XH Mao, Y Yan, J Liu, H Fan, Y Xu, W Sui, S Deng, ... Blood 136, 26-27, 2020 | 2 | 2020 |
| The prognostic impact of dynamic changes of genetic risk stratification in multiple myeloma H Fan, J Liu, C Yuan, XH Mao, LI Xiaoqing, X Du, Z Li, M Hao, Y Yan, ... Blood 136, 1-3, 2020 | 2 | 2020 |
| Genomic and transcriptomic profiling reveals distinct subsets associated with outcomes in mantle cell lymphoma Y Yan, S Yi, M Jin, Y Wang, Y Yu, W Jun, D Zou, T Wang, Z Yu, L Liu, ... Blood 136, 28-29, 2020 | 2 | 2020 |
